Literature DB >> 33329944

Assessment of Residual Radioactivity by a Comprehensive Wireless, Wearable Device in Thyroid Cancer Patients Undergoing Radionuclide Therapy and Comparison With the Results of a Home Device: A Feasibility Study.

R Gallicchio1, D Scapicchio1, A Nardelli2, T Pellegrino1, M Prisco1, P Mainenti2, C Sirignano2, P Pedicini1, G Storto1.   

Abstract

Objective: To investigate the feasibility of using a wireless wearable device (WD) in differentiated thyroid cancer (DTC) patients undergoing radionuclide therapy with I-131 (RAI) and protected hospitalization, this study compared the measurements of residual radioactivity obtained with those registered by a permanent environmental home device (HD).
Methods: Twenty consecutive patients undergoing RAI hospitalized in restricted, controlled areas were enrolled. The patients underwent comprehensive monitoring of vital/nonvital parameters. We obtained 45580± 13 measurements from the WD, detecting the residual radioactivity for each patient during approximately 56 hours of hospitalization, collecting data 53 times per hour. The samples, collected during daily activities, were averaged every two hours, and the results correlated with those from the HD. Bland-Altman analysis was also used to evaluate the agreement between the two techniques.
Results: A significant relationship between the WD and HD was observed (r = 0.96, p < 0.0001). Bland-Altman analysis recognized the agreement between measurements by the WD and HD. The mean value at the end of the first day of hospitalization was 80.81 microSv/h and 60.77 microSv/h (p = ns for WD and HD), whereas those at the end of the second day were 47.08 and 24.96 (p = ns). In the generalized linear model (GLM), a similar trend in performance across time was found with the two techniques.
Conclusion: This study demonstrates good agreement between the residual radioactivity measures estimated by the WD and HD modalities, rendering them interchangeable. This approach will allow both the optimization of medical staff exposure and safer patient discharge. Abbreviations: wireless device (WD); differentiated thyroid cancer (DTC); radionuclide therapy with I-131 (RAI); home device (HD); generalized linear model (GLM).

Entities:  

Keywords:  Wireless wearable device; permanent environmental home device; radiation exposure; residual radioactivity; thyroid cancer

Mesh:

Substances:

Year:  2020        PMID: 33329944      PMCID: PMC7732145          DOI: 10.1109/JTEHM.2020.3042118

Source DB:  PubMed          Journal:  IEEE J Transl Eng Health Med        ISSN: 2168-2372            Impact factor:   3.316


  27 in total

1.  Wireless medical sensor measurements of fatigue in patients with multiple sclerosis.

Authors:  Fei Yu; Arne Bilberg; Egon Stenager
Journal:  Annu Int Conf IEEE Eng Med Biol Soc       Date:  2010

2.  The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103.

Authors: 
Journal:  Ann ICRP       Date:  2007

3.  Detection of 131I in a patient with thyroid cancer by internal radiation exposure screening using a whole-body counter in Fukushima.

Authors:  Masaharu Tsubokura; Shuhei Nomura; Takeaki Ishii; Masahiro Kami; Shigeaki Kato
Journal:  Clin Nucl Med       Date:  2014-03       Impact factor: 7.794

4.  Uncertainties in estimating health risks associated with exposure to ionising radiation.

Authors:  R Julian Preston; John D Boice; A Bertrand Brill; Ranajit Chakraborty; Rory Conolly; F Owen Hoffman; Richard W Hornung; David C Kocher; Charles E Land; Roy E Shore; Gayle E Woloschak
Journal:  J Radiol Prot       Date:  2013-06-27       Impact factor: 1.394

5.  Understanding and characterisation of the risks to human health from exposure to low levels of radiation.

Authors:  Dudley T Goodhead
Journal:  Radiat Prot Dosimetry       Date:  2009-09-24       Impact factor: 0.972

6.  Uptake of ¹³¹I in households of thyroid cancer patients.

Authors:  David L North
Journal:  Health Phys       Date:  2013-04       Impact factor: 1.316

7.  Efficiency of whole-body counter for various body size calculated by MCNP5 software.

Authors:  D Krstic; D Nikezic
Journal:  Radiat Prot Dosimetry       Date:  2012-08-23       Impact factor: 0.972

8.  [Determination of radioactivity by smartphones].

Authors:  H Hartmann; R Freudenberg; M Andreeff; J Kotzerke
Journal:  Nuklearmedizin       Date:  2013       Impact factor: 1.379

9.  Teratogen update: radiation and Chernobyl.

Authors:  F P Castronovo
Journal:  Teratology       Date:  1999-08

10.  Radiation protection and dose monitoring in medical imaging: a journey from awareness, through accountability, ability and action…but where will we arrive?

Authors:  Donald Frush; Charles R Denham; Marilyn J Goske; James A Brink; Richard L Morin; Thalia T Mills; Priscilla F Butler; Cynthia McCollough; Donald L Miller
Journal:  J Patient Saf       Date:  2013-12       Impact factor: 2.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.